Organon & Co.

OGN

US68622V1061

Pharmaceuticals

Market Closed - Nyse Other stock markets 04:00:02 2025-01-15 pm EST			5-day change	1st Jan Change
15.73 ^USD	-0.51%		-1.69%	+5.43%

Jan. 13	Organon & Co. Presents at 43rd Annual J.P. Morgan Healthcare Conference 2025, Jan-13-2025 03:45 PM
Dec. 16	Organon Says Vtama Cream Approved by FDA for Atopic Dermatitis	MT

Organon Says FDA Extended Review of VTAMA's Supplemental New Drug Application

November 05, 2024 at 10:08 am EST

This article is reserved for members

To unlock the article, REGISTER!

100% Free Registration

Already a customer? Log In

Latest news about Organon & Co.

Organon & Co. Presents at 43rd Annual J.P. Morgan Healthcare Conference 2025, Jan-13-2025 03:45 PM	Jan. 13
Organon Says Vtama Cream Approved by FDA for Atopic Dermatitis	Dec. 16	MT
FDA Approves Organon & Co.'s Cream, 1% for the Treatment of Atopic Dermatitis in Adults and Children 2 Years of Age and Older	Dec. 16	CI
Organon & Co. Announces Resignation of Martha E. McGarry from the Board and as a Member of the Talent Committee of the Board	Dec. 06	CI
Organon Says FDA Extended Review of VTAMA's Supplemental New Drug Application	Nov. 05	MT
Organon : FDA Extends Vtama Atopic-Dermatitis Review to March	Nov. 05	DJ
Organon & Co. Updates on FDA Review of VTAMA Cream, 1% for the Treatment of Atopic Dermatitis in Adults and Children 2 Years of Age and Older	Nov. 05	CI
Organon Shares Rise After Q3 Revenue Beat	24-10-31	MT
Organon & Co., Q3 2024 Earnings Call, Oct 31, 2024	24-10-31
(OGN) ORGANON & CO. Sees Fiscal Year 2024 Revenue Range $6.38B - $6.43B	24-10-31	MT
Earnings Flash (OGN) ORGANON & CO. Reports Q3 Revenue $1.58B	24-10-31	MT
Earnings Flash (OGN) ORGANON & CO. Posts Q3 EPS $0.87	24-10-31	MT
Organon & Co. Revises Earnings Guidance for the Full Year 2024	24-10-31	CI
Organon & Co. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	24-10-31	CI
South Korea, US Discuss Trade Cooperation	24-10-31	MT
Organon Says US FDA Accepts Biologic License Application for Proposed Denosumab Biosimilar HLX14	24-10-30	MT
US FDA Accepts Biologics License Application for HLX14, Biosimilar Candidate of PROLIA/XGEVA	24-10-30	CI
Organon Finalizes Acquisition of Dermavant From Roivant	24-10-28	MT
EU regulator reviews anti-baldness drugs over concerns of suicidal thoughts	24-10-04	RE
Sector Update: Health Care Stocks Softer Friday Afternoon	24-10-04	MT
Sector Update: Health Care	24-10-04	MT
Organon's Propecia Medicine Under Review in Europe Over Risk of Suicidal Thoughts, Behaviors	24-10-04	MT
EU Health Regulator Reviews Hair Loss Drugs Over Potential Link to Suicidal Thoughts	24-10-04	MT
EU Health Regulator Reviews Hair Loss Drugs Over Potential Link to Suicidal Thoughts	24-10-04	MT
Organon's Propecia Medicine Under Review in Europe Over Risk of Suicidal Thoughts, Behaviors	24-10-04	MT

Organon & Co. is a global health care company. The Company is engaged in developing and delivering health solutions through a portfolio of prescription therapies and medical devices within women's health, biosimilars and a franchise of established medicines across a range of therapeutic areas. It has a portfolio of contraception and fertility brands, including Nexplanon, NuvaRing, and Follistim AQ. Its Biosimilars portfolio spans across immunology and oncology treatments. It also has a portfolio of established brands, including brands in cardiovascular, dermatology and non-opioid pain management. It sells these products through various channels, including drug wholesalers and retailers, hospitals, government agencies and managed health care providers, such as pharmacy benefit managers and other institutions. Its portfolio also includes VTAMA (tapinarof) cream, 1%, a nonbiologic, non-steroidal topical therapy, for treatment of mild, moderate, and severe plaque psoriasis in adults.

Employees

10,000

Sector

Pharmaceuticals

Calendar

2025-02-12 - Q4 2024 Earnings Release (Projected)

More about the company